CGRP: vom Neuropeptid zum therapeutischen Target (Hintergründe und
                    Pathophysiologie)

Katharina Kamm

doi:10.1055/a-2331-0783

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2024; 92(07/08): 267-276
DOI: 10.1055/a-2331-0783

Übersichtsarbeit

CGRP: vom Neuropeptid zum therapeutischen Target (Hintergründe und Pathophysiologie)

CGRP: from neuropeptide to the therapeutic target (background and pathophysiology)

Katharina Kamm

¹Neurologische Klinik und Poliklinik, LMU Klinikum Campus Grosshadern, Ludwig-Maximilians-Universität München, München, Germany (Ringgold ID: RIN27192)

› Author Affiliations

Abstract

Zusammenfassung

Calcitonin Gene-related Peptide (CGRP) spielt eine zentrale Rolle in der Pathophysiologie der Migräne. Die Bedeutung von CGRP für die Migräne ist aus zahlreichen klinischen Studien mit Nachweis von erhöhten CGRP-Spiegeln iktal und interiktal sowie der Wirksamkeit der CGRP-basierten Therapien bekannt. In der vorliegenden Arbeit werden diese Studien vorgestellt und so der Weg zur Entwicklung der CGRP-basierten Medikamente aufgezeigt. Abschließend werden aktuelle Studienergebnisse in Bezug auf die CGRP-Rezeptorantagonisten, die sogenannten Gepante, vorgestellt.

Abstract

Calcitonin gene-related peptide (CGRP) plays a pivotal role in migraine pathophysiology. The importance of CGRP in migraine became evident from numerous clinical studies investigating CGRP levels both interictally and ictally and reports on the efficacy of CGRP-based migraine therapies. In this paper, the above mentioned studies will be presented and the reader will be introduced to the development of CGRP-based medication. Finally, current study results on CGRP receptor antagonists, the so-called gepants, will be presented.

Schlüsselwörter

Migräne - Kopfschmerz - Calcitonin Gene-related Peptid - CGRP-Rezeptorantagonisten

Keywords

migraine - headache - CGRP receptor antagonists - Calcitonin gene-related peptide

Full Text

References

Literatur
1 Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiological reviews 2023; 103: 1565-644.
2 Russell FA, King R, Smillie S-J, Kodji X, Brain S. Calcitonin gene-related peptide: physiology and pathophysiology. Physiological reviews 2014; 94: 1099-1142
3 Meßlinger K. Bedeutung des „calcitonin gene-related peptide“ (CGRP) in der Pathophysiologie von Migräne und Clusterkopfschmerz. Der Schmerz 2020; 34: 181-187
4 Edvinsson L. CGRP and migraine: from bench to bedside. Revue neurologique 2021; 177: 785-790
5 Messlinger K. The big CGRP flood-sources, sinks and signalling sites in the trigeminovascular system. The Journal of Headache and Pain 2018; 19: 1-7
6 McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proceedings of the National Academy of Sciences 1986; 83: 5731-5735
7 Kamm K. CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?. Front Neurol.. 2022 Jul 27 13. 930383
8 Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nature Reviews Neurology 2018; 14: 338
9 Goadsby P, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 1990; 28: 183-187
10 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 1993; 33: 48-56
11 Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G. et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995; 15: 384-390
12 Ashina M, Hansen JM, Á Dunga BO, Olesen J Human models of migraine – short-term pain for long-term gain. Nature reviews Neurology. 2017 13. 713
13 Juhász G, Zsombok T, Jakab B, Nemeth J, Szolcsányi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 2005; 25: 179-183
14 Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J. et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106: 461-70.
15 Sarchielli P, Pini LA, Zanchin G, Alberti A, Maggioni F, Rossi C. et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 2006; 26: 257-265
16 Gárate G, González-Quintanilla V, González A, Pascual M, Pérez-Pereda S, Madera J. et al. Serum alpha and beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann Neurol. 2023 94. 285-294 Epub 2023 Apr 21
17 Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000; 86: 133-138
18 Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013; 81: 1191-1196
19 Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A. et al. CGRP and PTX3 as predictors of efficacy of Onabotulinumtoxin type a in chronic migraine: an observational study. Headache: The Journal of Head and Face Pain 2018; 58: 78-87
20 Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 2007; 128: 209-214
21 Lee MJ, Lee S-Y, Cho S, Kang E-S, Chung C-S. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. The journal of headache and pain 2018; 19: 53
22 Pérez-Pereda S, Toriello-Suárez M, Ocejo-Vinyals G, Guiral-Foz S, Castillo-Obeso J, Montes-Gómez S. et al. Serum CGRP, VIP, and PACAP usefulness in migraine: a case – control study in chronic migraine patients in real clinical practice. Molecular Biology Reports 2020; 47: 7125-7138
23 Raffaelli B, Storch E, Overeem LH, Terhart M, Fitzek MP, Lange KS. et al. Sex hormones and calcitonin gene-related peptide in women with migraine: a cross-sectional, matched cohort study. Neurology 2023; 100: e1825-e1835
24 Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R. Endothelial progenitor cells: a new key for endothelial dysfunction in migraine. Neurology 2012; 79: 474-479
25 Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 2005; 58: 561-568
26 Messlinger K, Vogler B, Kuhn A, Sertel-Nakajima J, Frank F, Broessner G. CGRP measurements in human plasma – a methodological study. Cephalalgia 2021; 41: 1359-1373
27 Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP can monitor the different migraine phases: CGRP (in) dependent attacks. Cephalalgia. 2021 03331024211040467
28 Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache: The Journal of Head and Face Pain 2006; 46: 24-33
29 Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache: The Journal of Head and Face Pain 2009; 49: 1258-1266
30 Jang MU, Park JW, Kho HS, Chung SC, Chung JW. Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. Oral diseases 2011; 17: 187-193
31 Nicolodi M, Bianco ED. Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache. Cephalalgia 1990; 10: 39-50
32 Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP and erenumab treatment response: towards precision medicine in migraine. Annals of Neurology 2022; 92: 846-859
33 Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia 2019; 39: 1535-1543
34 Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache: The Journal of Head and Face Pain 2018; 58: 33-47
35 Juhasz G, Gecse K, Baksa D. Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response. Pharmacology & Therapeutics. 2023: 108523
36 Labastida-Ramírez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D. et al. Mode and site of action of therapies targeting CGRP signaling. The Journal of Headache and Pain 2023; 24: 125
37 Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U. et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine 2004; 350: 1104-1110
38 Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F. Gepants – a long way to cure: a narrative review. Neurological Sciences 2022; 43: 5697-5708
39 Li D, Abreu J, Tepper SJ. A Brief Review of Gepants. Current Pain and Headache Reports 2023; 27: 479-488
40 Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X. et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014; 83: 958-966
41 Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM. et al. Ubrogepant for the treatment of migraine. New England Journal of Medicine 2019; 381: 2230-2241
42 Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG. et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 2019; 394: 737-745
43 Ailani J, Lipton BR, Goadsby JP, Guo H, Miceli R, Severt L, Finnegan M, Trugman MJ. ADVANCE Study Group. Atogepant for the Preventive Treatment of Migraine. N Engl J Med. 2021 Aug 19 385(8). 695-706
44 Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A. et al. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache: The Journal of Head and Face Pain 2022; 62: 1153-1163